Inclusion Criteria:

- Subjects must have a histologically confirmed NSCLC or clinical and imaging evidence
of a de novo mass that is likely to be a NSCLC, stage I, II, or IIIA, for which
surgery would be indicated for routine medical indications

- ECOG performance status between 0 and 2

- Subjects must sign an informed consent document that indicates they are aware of the
investigational nature of the treatment in this protocol as well as the potential
risks and benefits

- WBC > 2,000/mm^3

- Platelet count > 100,000/mm^3

- Total bilirubin

- Serum AST and ALT

- Serum creatinine

- Negative serum pregnancy test if a female of childbearing age

Exclusion Criteria:

- History of allergic reactions attributed to Flagyl (metronidazole), which has a
chemical structure similar to EF5

- Uncontrolled intercurrent illness that would limit compliance with study requirements

- Pregnant women and women who are breastfeeding are excluded

- Subjects who have been treated with neoadjuvant radiation or chemotherapy prior to
their biopsy or excision are excluded because the impact of these therapies upon the
degree of hypoxia of the tumor is unknown